%0 Journal Article %A Tang, Shengnan %A Wang, Aiping %A Yan, Xiuju %A Chu, Liuxiang %A Yang, Xiucheng %A Song, Yina %A Sun, Kaoxiang %A Yu, Xin %A Liu, Rongxia %A Wu, Zimei %A Xue, Peng %D 2019 %T Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease %U https://tandf.figshare.com/articles/journal_contribution/Brain-targeted_intranasal_delivery_of_dopamine_with_borneol_and_lactoferrin_co-modified_nanoparticles_for_treating_Parkinson_s_disease/8851424 %R 10.6084/m9.figshare.8851424.v1 %2 https://tandf.figshare.com/ndownloader/files/16216277 %K Dopamine %K lactoferrin %K borneol %K nose-to-brain targeted nanoparticles %K Parkinson’s disease %X

Efficient delivery of brain-targeted drugs is highly important for successful therapy in Parkinson’s disease (PD). This study was designed to formulate borneol and lactoferrin co-modified nanoparticles (Lf-BNPs) encapsulated dopamine as a novel drug delivery system to achieve maximum therapeutic efficacy and reduce side effects for PD. Dopamine Lf-BNPs were prepared using the double emulsion solvent evaporation method and evaluated for physicochemical and pharmaceutical properties. In vitro cytotoxicity studies indicated that treatment with dopamine Lf-BNPs has relatively low cytotoxicity in SH-SY5Y and 16HBE cells. Qualitative and quantitative cellular uptake experiments indicated that Lf modification of NPs increased cellular uptake of SH-SY5Y cells and 16HBE cells, and borneol modification can promote the cellular uptake of 16HBE. In vivo pharmacokinetic studies indicated that AUC0–12 h in the rat brain for dopamine Lf-BNPs was significantly higher (p < .05) than that of dopamine nanoparticles. Intranasal administration of dopamine Lf-BNPs effectively alleviated the 6-hydroxydopamine-induced striatum lesion in rats as indicated by the contralateral rotation behavior test and results for striatal monoamine neurotransmitter content detection. Taken together, intranasal administration of dopamine Lf-BNPs may be an effective drug delivery system for Parkinson’s disease.

%I Taylor & Francis